FibroGen (NASDAQ:FGEN) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of FibroGen (NASDAQ:FGEN) in a research note published on Friday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th.

FibroGen Stock Performance

FGEN stock opened at $0.40 on Friday. The company has a 50 day moving average price of $0.36 and a two-hundred day moving average price of $0.68. The stock has a market capitalization of $39.84 million, a P/E ratio of -0.32 and a beta of 0.72. FibroGen has a one year low of $0.18 and a one year high of $2.93.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21. The business had revenue of $46.33 million during the quarter, compared to analysts’ expectations of $34.00 million. During the same period in the prior year, the firm earned ($0.52) EPS. Research analysts forecast that FibroGen will post -0.86 earnings per share for the current fiscal year.

Institutional Trading of FibroGen

Several institutional investors have recently made changes to their positions in FGEN. Acadian Asset Management LLC boosted its holdings in FibroGen by 34.4% in the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock valued at $2,997,000 after acquiring an additional 860,854 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of FibroGen by 139.6% in the 2nd quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock valued at $1,179,000 after purchasing an additional 769,586 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of FibroGen during the 3rd quarter worth about $307,000. XTX Topco Ltd purchased a new stake in shares of FibroGen during the 2nd quarter worth about $424,000. Finally, Cubist Systematic Strategies LLC increased its position in FibroGen by 3,906.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 280,161 shares in the last quarter. 72.71% of the stock is owned by hedge funds and other institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.